BEAT HeartBeam, Inc. stock chart & analysis
Conviction 36HealthcareScan · Thu, Nov 19, 2026HeartBeam, Inc. (BEAT) closed at $0.3082 (-9.46%) on Nov 19, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 34, RS Rating 5, -92.3% from its 52-week high, -87.2% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.
Why BEAT moved
From the StockSetups movers recaps that covered BEAT, newest first. A recap states what was known that day.
- Close+54.0%
HeartBeam, Inc. (BEAT) surged +54.0% to close at $0.67 on volume of 156,264,569 shares — nearly 19× its 20-day average of 8,288,978. The stock gapped up +72.3% at the open before trimming gains slightly into the close.
Top Stock Movers Oct 5, 2026: MI, VEEA, BEAT → - Premarket+88.2%
HeartBeam received an FDA Breakthrough Device Designation for its heart attack assessment technology, according to Yahoo Finance and Stock Titan this morning.
Premarket Movers Oct 5, 2026: MI, BEAT, ALEC →
Financials as of Wed, Sep 30, 2026 · quarterly.
BEAT technical analysis
Trend
BEAT is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 27.1% below the 50-day ($0.4228) and 60.0% below the 200-day ($0.7706). ADX(14) at 18 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 34, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.
Volume and volatility
Volume on the latest session ran 0.1× its 20-day average. It trades about $569,744 a day on average. ATR(14) is $0.0426, 13.8% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.09) shows accumulation.
Key levels
The chart pattern's support is $0.3691 and its resistance $0.7623. The 52-week range is $0.3000 to $4.00; price is 92.3% below the high and 2.7% above the low. The VWAP anchored at the 52-week high is $1.06, above price.
Performance
BEAT returned -23.7% (1 week), -24.3% (1 month), -37.5% (3 months), -66.5% (6 months), -81.9% (1 year), -87.2% (year to date).
About HeartBeam, Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
Surgical & Medical Instruments & Apparatus · Listed 2021 · 17 employees
Insider activity
SEC Form 4 transactions in BEAT
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Ortigas-Wedekind Marga Director · Restricted Stock Units · 2026-10-02 | Grant | 93.75K | — | 2026-10-02 | 2026-10-09 |
de Urioste George Director · Stock Option (Right to Buy) · 2026-10-02 | Grant | 93.75K | — | 2026-10-02 | 2026-10-09 |
JAFF MICHAEL R Director · Restricted Stock Units · 2026-10-02 | Grant | 37.5K | — | 2026-10-02 | 2026-10-09 |
Elfrink Willem Director · Restricted Stock Units · 2026-10-02 | Grant | 93.75K | — | 2026-10-02 | 2026-10-09 |
Elfrink Willem Director · Stock Option (right to buy) · 2026-10-02 | Grant | 93.75K | — | 2026-10-02 | 2026-10-09 |
Ferrari Richard Director · Restricted Stock Units · 2026-10-02 | Grant | 125K | — | 2026-10-02 | 2026-10-09 |
Ferrari Richard Director · Restricted Stock Units · 2026-10-02 | Grant | 90.63K | — | 2026-10-02 | 2026-10-09 |
Ferrari Richard Director · Stock Option (Right to Buy) · 2026-10-02 | Grant | 125K | — | 2026-10-02 | 2026-10-09 |
de Urioste George Director · Restricted Stock Units · 2026-10-02 | Grant | 93.75K | — | 2026-10-02 | 2026-10-09 |
Nelson Kenneth Warwick III Director · Restricted Stock Units · 2026-10-02 | Grant | 93.75K | — | 2026-10-02 | 2026-10-09 |
SEC filings
EDGAR filings in BEAT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.